Comparison of disease severity in glaucoma patients identified by screening in the 1990s and in routine clinical care in the 2010s in Sweden.

BACKGROUND AND PURPOSE: In a previous study comparing the amount of visual field damage at presentation in patients having open-angle glaucoma (OAG) identified through screening and in patients diagnosed in routine clinical practice in the 1990s, the damage was considerably worse in the clinically diagnosed patients. In the present study we compare visual field damage at presentation in the same 402 screened patients with that seen in 281 newly detected previously untreated patients clinically diagnosed in the 2010s. METHODS: The perimetric visual field index mean deviation (MD) was compared in the two groups of patients. RESULTS: In the clinical patients diagnosed with bilateral visual field damage the median MD was -5.1 dB in the better eye and -13.0 dB in the worse eye. In the screened patients the median MD in the better eye was -6.5 dB and -11.5 dB in the worse eye. The differences between the clinical and screened patients were non-significant, p = 0.28 and p = 0.67 respectively. More clinical patients had severe visual field loss, defined as MD less than -20 dB, in the worse eye than in the screened patients, 18.5% versus 12.7% respectively, p = 0.037. CONCLUSION: The visual field damage at presentation in clinically diagnosed OAG patients has improved in the past 20 years, but the proportion of patients with severe visual field loss in at least one eye, almost 20%, is still unacceptably high considering that severe visual field damage at presentation is the most important risk factor for later development of glaucoma blindness.

Caracterización de la población con anemia en el embarazo y su asociación con la morbimortalidad perinatal / Characterization of pregnant population with anemia and asociation with perinatal morbimortality

Resumen Introducción: la anemia es el trastorno nutricional más frecuente en el mundo y en el embarazo constituye un riesgo para la madre, el feto o recién nacido, desencadenando complicaciones como IVU, aborto, RCIU, parto prematuro, preeclampsia, bajo peso al nacer, RPM, etc. Objetivo: Determinar los efectos de la anemia en el embarazo y el desenlace perinatal de las pacientes atendidas en el Hospital Universitario Hernando Moncaleano de Neiva en el periodo de junio de 2012 a junio de 2016. Metodología: Se realizó un estudio observacional, descriptivo, retrospectivo, en gestantes atendidas en consulta de alto riesgo obstétrico durante el periodo e institución mencionados, con cruce de variables para determinar la relación entre la gravedad de la anemia y sus complicaciones mediante el cálculo del Chi-cuadrado Resultados: De 1.493 pacientes, 101 mujeres embarazadas entre los 16 a 34 años fueron incluidas en el estudio. La prevalencia de anemia fue de 32.01% y las complicaciones identificadas fueron: Infección de vías urinarias (8,91%), restricción de crecimiento intrauterino (7,9%), bajo peso al nacer (6,9%), preeclampsia (4,95%), parto prematuro (3,96%), ruptura prematura de membranas (3,03%) y un solo caso de aborto. El 10,89% de los recién nacidos requirieron hospitalización, de los cuales 2 presentaron hipoglicemia y 5 ictericia neonatal. Conclusiones: La anemia es una patología subdiagnosticada que afecta a mujeres entre los 16 y 30 años cuyas complicaciones como bajo peso al nacer, restricción de crecimiento intrauterino e ictericia neonatal resultan dependientes de la gravedad de la anemia.

Abstract Introduction: Anemia is the most frequent nutritional disorder in the world and in pregnancy it is a risk for the mother, the fetus or newborn, triggering complications such as IVU, abortion, IUGR, preterm birth, preeclampsia, low birth weight, RPM, etc. Objective: To determine the effects of anemia on pregnancy and the perinatal outcome of the patients treated at the Hernando Moncaleano Hospital in Neiva from June 2012 to June 2016. Methodology: An observational, descriptive, retrospective study, In pregnant women attended at a high obstetrical risk visit during the period and institution mentioned, with cross-variables to determine the relationship between the severity of the anemia and its complications by the Chi-square calculation Results: Of 1,493 patients, 101 pregnant women Between the ages of 16 and 34 were included in the study. The prevalence of anemia was 32.01% and the complications identified were: Urinary tract infection (8.91%), intrauterine growth restriction (7.9%), low birth weight (6.9%), preeclampsia, 95%), preterm delivery (3.96%), premature rupture of membranes (3.03%) and a single case of abortion. 10.89% of the newborns required hospitalization, of which 2 had hypoglycemia and 5 neonatal jaundice. Conclusions: Anemia is an underdiagnosed pathology that affects women between 16 and 30 whose complications such as low birth weight, intrauterine growth restriction and neonatal jaundice are dependent on the severity of the anemia.

Endocarditis infecciosa nativa en pediatría: enfoque clínico cardiológico / Native valve infective endocarditis in children: From the focus of clinical cardiology

Objetivos: Analizar las características demográficas, clínicas, microbiológicas, evolución y factores de riesgo de morbimortalidad asociados a la endocarditis de válvula nativa (EIN) en pacientes (p) pediátricos. Población y métodos: Se evaluaron 176 p con EIN, divididos en grupo I: <3meses (27p) y grupo II: >3meses (149p). Resultados: Grupo I: el 66% tenía corazón sano. El microorganismo más frecuente fue Staphylococcus aureus (44,4%). Afectación derecha (77,8%-p<0,0001). Evento principal: infección no controlada (INC) (52%, p=0,0009) y asociada a Candida (p<0,00001). Se indicó tratamiento quirúrgico a 10 p (37%). Mortalidad 29,6%(8p). Grupo II: el 57% presentaba cardiopatía previa. Microorganismos prevalentes: S.aureus (49,1%) y estreptococos del grupo viridans (22,5%). Hubo compromiso predominantemente izquierdo (p=0,001). Eventos: embolias sistémicas (36,2%-p=0,01), perforación valvular (51%-p=0,0005), insuficiencia cardíaca (26%-p=0,03) e INC (21,5%). La embolia sistémica se asoció a S.aureus (p=0,01). El 36,2% requirió cirugía. Mortalidad 6,7% (10p). En el análisis univariado la mortalidad se asoció a edad <3meses (p=0,0003), INC (p=0,002) y S.aureus (p=0,03). En el multivariado la mortalidad se relacionó a edad < 3meses (OR:7,50 ­IC95%:1,77­31,69) y a INC (OR:4,2-IC95%:1,16­15,29). Conclusiones: La EN se presentó en pacientes con corazón sano en el 50% de los casos. El microorganismo más frecuente fue S.aureus. En los <3 meses la infección no controlada fue la complicación más frecuente asociada a Candida, con afectación predominante de cavidades derechas. Los >3meses tuvieron mayor prevalencia de perforación valvular izquierda asociada a embolias sistémicas e insuficiencia cardíaca. El 35% de los p requirió cirugía. Los predictores de mortalidad fueron la edad <3meses y la INC.

Objectives: To analyze demographic, clinical, and microbiological, outcome, and morbidity and mortality risk factors associated with native valve endocarditis (NVE) in pediatric patients (p). Population and methods: 176 p with NVE were evaluated and divided into group I: <3 months (27p) and group II: >3 months (149p). Results: Group I: 66% had a healthy heart. The most common microorganism was Staphylococcus aureus (44.4%). Right-sided involvement (77.8%-p<0.0001). Main event: Uncontrolled infection (UCI) (52%, p-0.0009) and association with Candida (p<0.00001). Surgical treatment was indicated in 10 p (37%). Mortality was 29.6% (8p). Group II: 57% had previous heart disease. Prevalent microorganisms: S. aureus (49.1%) and viridans group streptococci ( (22.5%). Left-sided involvement predominated (p-0.001). Events: systemic embolism (36.2%-p-0.01), valve perforation (51%-p-0.0005), heart failure (26%-p-0.03), and UCI (21.5%). Systemic embolism was associated with S. aureus infection (p-0.01). 36.2% required surgery. Mortality was 6.7% (10p). In univariate analysis, mortality was associated with age <3 months (p-0.0003), UCI (p-0.002), and S. aureus infection (p-0.03). In multivariate analysis, mortality was related to age <3 months (OR:7.50 ­ 95% CI:1.77­31.69) and UCI (OR:4.2 -95% CI:1.16­15.29). Conclusions: NVE was observed in patients with a healthy heart in 50% of cases. The most common microorganism found was S. aureus. In the <3 months group, uncontrolled infection was the most common complication associated with Candida, predominantly affecting the right side. The >3 months group had a higher prevalence of left-valve perforation associated with systemic embolism and heart failure. 35% of p required surgery. Predictors of mortality were age <3 months and UC (AU)

Consultorio de orientaciòn de cardilogía: epidemiología y perfil de la población / Cardiology guidance clinic: Epidemiology and profile of the population

Introducción: Las cardiopatías congénitas (CC) son las anomalías congénitas más frecuentes. Representan el 0,8-1,2% de todos los defectos del nacimiento y tienen una prevalencia de alrededor de 5,8 por cada 1000 personas. El Servicio de Cardiología del Hospital Garrahan es un centro de referencia nacional y de países limítrofes donde se realizan 18000 consultas anuales. Los pacientes que concurren por primera vez se atienden en el consultorio de orientación. Objetivo: Describir la epidemiologia y perfil de los pacientes que asisten diariamente al consultorio de orientación de cardiología infantil en un hospital pediátrico de tercer nivel de Buenos Aires. Métodos: Entre septiembre de 2017 y febrero de 2018 se recolectaron los datos de 1000 pacientes atendidos en forma consecutiva en el consultorio de orientación de cardiología. A la totalidad de los pacientes se les realizó anamnesis, examen físico cardiovascular, electrocardiograma, y en los casos en los que se consideró necesario, saturometría, radiografía de tórax y/o ecocardiograma. Las variables a considerar fueron edad, procedencia, presencia o ausencia de cardiopatías congénitas o adquiridas, soplo, cianosis, insuficiencia cardíaca, estado nutricional, síndromes genéticos asociados, métodos diagnósticos e indicaciones terapéuticas implementadas. Se subdividió la población en cinco grupos: Grupo A (pacientes con cardiopatía congénita), Grupo B (cardiopatías operadas), Grupo C (miocardiopatías), Grupo D (arritmias), Grupo E (corazón sano). Resultados: La edad mediana fue 4.86 años (0.03 a 18.9 años). El 64% de los pacientes procedían de la provincia de Buenos Aires. Los motivos de consulta fueron: interconsultas internas 29.5%, derivación por cardiopatía 27.2%, soplo 17.6%, síncope 7%, segunda opinión 5.1%, arritmias 4.8%, precordialgia 3.1%, palpitaciones 2.6%, episodio paroxístico 1.4%, cardiomegalia 0.7%, disnea 0.5%, mal progreso de peso 0.3%. El 10.6% tenían un síndrome genético. Grupo A: 252 pacientes con una edad mediana de 1.9 años. Las cardiopatías acianóticas con hiperflujo pulmonar fueron las más frecuentes (66.66%, 168/252). Grupo B: 51 pacientes, 23.52%(12/51) fueron Fallot reparados en otra institución. Grupo C: 22 pacientes, siendo la miocardiopatía hipertrófica la más frecuente. Grupo D: 47 pacientes, la preexcitación ventricular fue el hallazgo más frecuente (34,04%, 16/47). Grupo E: 628 pacientes, 45.70% (287/628) derivados por pediatras del área ambulatoria, principalmente para valoración de pacientes con enfermedades sistémicas o síndromes genéticos. Conclusión: Los motivos de derivación al consultorio de orientación de cardiología fueron muy diversos. La mayoría de los pacientes provenían de provincia de Buenos Aires. Solamente el 37.2% presentó algún problema cardiológico de base. El 91% de los pacientes que consultaron por soplo, no tuvieron cardiopatía. El grupo correspondiente a los pacientes con cardiopatías no operadas (grupo A) fue el de menor edad (mediana de 1.9 años) y las cardiopatías simples no cianóticas con hiperflujo pulmonar representaron el 66.66% de las cardiopatías. La implementación del ecocardiograma portátil en el consultorio de orientación permitió confirmar el diagnóstico y definir la conducta terapéutica en el 29.4% de los pacientes durante la primer consulta (AU)

Introduction: Congenital heart defects (CHD) are the most common congenital abnormalities. They account for 0.8-1.2% of all birth defects and have a prevalence of around 5.8 per 1000 people. The Department of Cardiology of Garrahan Hospital is a national and bordering-country reference center, receiving 18000 consultations annually. Patients seen for the first time are assessed at the cardiology guidance clinic. Objective: To describe the epidemiology and profile of patients who seen daily at the child cardiology guidance clinic of a third-level pediatric hospital in Buenos Aires. Methods: Between September 2017 and February 2018, data from 1000 patients consecutively seen at the cardiology guidance clinic were collected. All patients underwent anamnesis, cardiovascular physical examination, electrocardiogram and, if considered necessary, pulse oximetry, chest x-ray, and/or echocardiogram. The variables considered were age, place of origin, presence or absence of congenital or acquired heart disease, murmur, cyanosis, heart failure, nutritional status, associated genetic syndromes, diagnostic methods, and treatment. The population was divided into five groups: Group A (patients with congenital heart defects), Group B (operated cardiopathies), Group C (myocardiopathies), Group D (arrhythmias), Group E (healthy heart). Results: Median age was 4.86 years (0.03 to 18.9 years). Overall, 64% of patients came from the province of Buenos Aires. The reasons for consultation were: internal consultations 29.5%, cardiac shunt 27.2%, murmur 17.6%, syncope 7%, second opinion 5.1%, arrhythmias 4.8%, precordialgia 3.1%, palpitations 2.6%, paroxysmal episode 1.4%, cardiomegaly 0.7%, dyspnea 0.5%, 0.3% poor weight gain. A genetic syndrome was identified in 10.6%. Group A: 252 patients with a median age of 1.9 years. Acyanotic congenital heart defect with pulmonary hyperflow was the most common (66.66%, 168/252). Group B: 51 patients, 23.52% (12/51) had tetralogy of Fallot repaired at another institution. Group C: 22 patients, in whom hypertrophic cardiomyopathy was the most common. Group D: 47 patients, in whom ventricular preexcitation was the most common finding (34.04%, 16/47). Group E: 628 patients, 45.70% (287/628) referred by pediatricians from the outpatient clinics, mainly for the assessment of systemic diseases or genetic syndromes. Conclusion: The reasons for referral to the cardiology guidance clinic were varied. Most of the patients came from the province of Buenos Aires. Only 37.2% had an underlying heart disease. Of the patients who consulted because of a murmur, 91% did not suffer from heart disease. The group of patients with congenital heart disease who had not undergone surgery (group A) was the youngest (median 1.9 years) and simple non-cyanotic heart disease with pulmonary hyperflow accounted for 66.66% of heart diseases. The implementation of the portable echocardiography in the guidance clinic confirmed the diagnosis and defined the management in 29.4% of patients during the first consultation (AU)

Insuficiencia cardíaca en pediatría / Heart failure in children

La Insuficiencia Cardíaca (IC) es un síndrome clínico que epresenta una de las mayores causas de mobi-mortalidad en pacientes pediátricos. Refleja la incapacidad del corazón para satisfacer las necesidades metabólicas del organismo, incluido el crecimiento y el ejercicio. En el niño la causa más frecuente es la cardiopatía congénita. Otras causas las miocardiopatía, las miocarditis, las arritmias y las causas no cardíacas como: insuficiencia renal, hipertensión arterial, enfermedades pulmonares crónicas, anemia, sepsis, hiper e hipotiroidismo, cardiotoxicidad, etc. Clásicamente el tratamiento estaba dirigido a mejorar la contractilidad y evitar la retención hidrosalina con digital y diuréticos. En la actualidad, dado a la mejor comprensión del mecanismo fisiopatológico, en los últimos años, el tratamiento se centra en el control de los sistemas renina-angiotensina (SRAA) y nervioso simpático. En los casos de IC descompensada que presentan síndrome de bajo gasto cardíaco que no responde a la terapia médica, previo al trasplante cardíaco, está indicado el soporte mecánico (AU)

Heart failure (HF) reflects the inability of the heart to meet the metabolic needs of the body, including growth and exercise. In the child, the most common cause is congenital heart disease. Other causes are cardiomyopathy, myocarditis, arrhythmias, and non-cardiac causes, such as renal failure, high blood pressure, chronic pulmonary diseases, anemia, sepsis, hyper- and hypothyroidism, cardiotoxicity. Classically, the treatment aimed at improving contractility and avoiding salt and fluid retention using digitalis and diuretics. Given the current better understanding of the pathophysiological mechanism, over the past years treatment has focused on the control of renin-angiotensin (RAAS) and sympathetic nervous systems. In cases of decompensated HF with low cardiac output syndrome not responding to medical therapy, prior to cardiac transplantation mechanical support is indicated (AU)

El adolescente con cardiopatía congénita: transición y transferencia / The adolescent with congenital heart defects: transition and transfer

Introducción: Los grandes avances en el diagnóstico y tratamiento de los pacientes con cardiopatías congénitas en las últimas décadas han permitido que mas del 90% lleguen a la adolescencia y edad adulta. Sin embargo, muchos de ellos requirieran seguimiento e intervenciones de por vida, por lo que necesitaran ser transferidos desde el hospital pediátrico al de adultos. Material y Métodos: Se incluyeron los pacientes mayores de 15 años que consultaron en el área ambulatoria del servicio de cardiología del Hospital Garrahan durante el periodo agosto 2017 - agosto 2018. Las variables analizadas fueron: procedencia, cardiopatía de base y variedad pronostica ,procedimientos intervencionistas factores asociados como síndrome genéticos y otras comorbilidades, cobertura social, nivel educativo, terapéutica medicamentosa, clase funcional, embarazos, prevalencia de cardiopatías en la descendencia y transición-transferencia al hospital de adultos. Resultados: Registramos 704 consultas de 309 pacientes con una edad media de 19,17 años (DS +- 4,62; (rango 15- 49,4 años). Fueron 112 mujeres y 197 varones. El 51,1 % provenían de Buenos Aires,40 % de las provincias del interior y 8,1% CABA. El 92% de los pacientes tenía cardiopatías de moderada y severa complejidad, y el 93,5% eran operadas. El 13,2 % eran síndromes genéticos. El 48.5% tenían comorbilidades, siendo los trastornos electrofisiológicos los más frecuentes en el 72,66% de los casos. El 63% tenía cobertura social pero solo el 2,6% prepagos con cobertura en centros alta complejidad. El 23.6% recibía terapia combinada con 2 o más drogas. El 48,78% ya presentaban antecedente de algún tipo de reintervención, 98,5% de estas se vincularon a las cardiopatías moderadas a complejas. Registramos 15 embarazos con 14 recién nacidos vivos, 1 con cardiopatía congénita. El proceso de transición ­ transferencia en el 55% (170 p) se había iniciado, siendo efectiva (8p), frustra (9p), compartida (49 p), y en proceso (103 p). Hubo un solo fallecimiento durante el periodo de estudio, vinculado a cardiopatía compleja, múltiples reintervenciones y endocarditis. Conclusiones: El 92% de los pacientes en nuestro estudio, tienen cardiopatías operadas de moderada y severa complejidad. Los trastornos electrofisiológicos y la necesidad de reintervenciones durante el seguimiento alejado han sido las complicaciones más frecuentes de esta población. El proceso de transición y transferencia desde el hospital pediátrico al de adultos es deficitario, principalmente por falta de cobertura y experiencia sobre todo para la atención continua de las cardiopatías moderadas y complejas (AU)

Introduction: In recent decades, important advances in the diagnosis and treatment of patients with congenital heart defects have allowed more than 90% of them to reach adolescence and adulthood. However, many patients required lifelong follow-up and interventions, and therefore the need to be transitioned from pediatric to adult care. Material and Methods: Patients older than 15 years who consulted at the outpatient clinic of the department of cardiology at Garrahan Hospital from August 2017 to August 2018 were included. The variables analyzed were place of origin, underlying heart disease, and diagnosis, interventions, associated factors, such as genetic syndromes and other comorbidities, insurance coverage, educational level, pharmacological treatment, functional class, pregnancies, prevalence of heart disease in offspring, and transition-transfer to adult hospital. Results: We recorded 704 consultations from 309 patients with an average age of 19.17 years (SD +- 4.62; range 15-49.4 years); 112 patients were female and 197 male. Overall, 51.1% came from the province of Buenos Aires, 40% from the other provinces, and 8.1% from the city of Buenos Aires. Of the patients, 92% had moderate and severe heart disease, and 93.5% had undergone surgery. Genetic syndromes were identified in 13.2%. Overall, 48.5% had comorbidities, of which electrophysiological disorders were the most common in 72.66% of cases. 63% had social insurance coverage but only 2.6% had a prepaid insurance with coverage in tertiary-level centers. Overall, 23.6% received combination therapy with 2 or more drugs. 48.78% had undergone some type of previous reintervention, 98.5% of whom had moderate-to-severe heart disease. We recorded 15 pregnancies with 14 live neonates, one of whom had congenital heart defects. The transition - transfer had been initiated in 55% (170 p) and was effective (8p), frustrated (9p), shared (49 p), or in progress (103 p). There was only one death during the study period, related to severe heart disease, multiple reinterventions, and endocarditis. Conclusions: 92% of patients in our study have moderate or severe operated heart disease. Electrophysiological disorders and the need for reintervention during the long-term follow-up were the most common complications of this population. The process of transition and transfer from pediatric to adult care is deficient, mainly due to lack of insurance coverage and experience especially for the ongoing care of moderate-to-severe heart disease

Cardiopatías congénitas y nuevas técnicas de diagnóstico no invasivo: Tomografía computada multidetector (TCMD) / Congenital heart defects and new non-invasive diagnostic techniques: Multidetector computed tomography (MDCT)

Las cardiopatías congénitas presentan con frecuencia patrones anatómicos complejos y tradicionalmente se han estudiado con ecocardiografía y eventualmente con cateterismo cardíaco. Con los avances tecnológicos de las últimas décadas, la tomografía computada y la resonancia magnética nuclear han adquirido gran importancia en la evaluación cardíaca. Actualmente constituyen métodos utilizados en el estudio de variadas patologías cardiovasculares de la infancia de difícil diagnóstico ecográfico, que previamente eran evaluadas por angiografía convencional, lo cual implicaba una dosis de radiación mucho mayor (AU)

Congenital heart defects often have complex anatomical patterns and have traditionally been studied with echocardiography and eventually cardiac catheterization. With technological advances in recent decades, computed tomography and magnetic resonance imaging have become very important in cardiac evaluation. Currently, they are the methods of choice in the study of a wide range of childhood cardiovascular diseases that are difficult to diagnose with echocardiography, which were previously evaluated using conventional angiography, involving a much higher dose of radiation (AU)

Aspectos metodológicos de los procesos asistenciales integrados (PAI) / Methodological aspects of integrated care pathways

Un proceso asistencial integrado (PAI) es una herramienta cuyo propósito es aumentar la efectividad de las actuaciones clínicas a través de una mayor coordinación y garantía de continuidad asistencial. Los PAI sitúan al paciente como el eje central de la organización asistencial. Se definen como el conjunto de actividades que realizan los proveedores de la atención sanitaria con la finalidad de incrementar el nivel de salud y el grado de satisfacción de la población que recibe los servicios. La elaboración de un PAI precisa analizar el flujo de actividades, la interrelación entre profesionales y dispositivos asistenciales y las expectativas del paciente. En este artículo se presenta y se discute la metodología para la elaboración de un PAI, así como los factores de éxito para su definición y su efectiva implantación. Se explica también, a modo de ejemplo, el reciente PAI para hipoglucemias en personas con diabetes mellitus tipo 2 elaborado por un equipo multidisciplinar y avalado por varias sociedades científicas (AU)

An Integrated Healthcare Pathway (PAI) is a tool which has as its aim to increase the effectiveness of clinical performance through greater coordination and to ensure continuity of care. PAI places the patient as the central focus of the organisation of health services. It is defined as the set of activities carried out by the health care providers in order to increase the level of health and satisfaction of the population receiving services. The development of a PAI requires the analysis of the flow of activities, the inter-relationships between professionals and care teams, and patient expectations. The methodology for the development of a PAI is presented and discussed in this article, as well as the success factors for its definition and its effective implementation. It also explains, as an example, the recent PAI for Hypoglycaemia in patients with Type 2 Diabetes Mellitus developed by a multidisciplinary team and supported by several scientific societies (AU)

[Methodological aspects of integrated care pathways]. / Aspectos metodológicos de los procesos asistenciales integrados (PAI).

An Integrated Healthcare Pathway (PAI) is a tool which has as its aim to increase the effectiveness of clinical performance through greater coordination and to ensure continuity of care. PAI places the patient as the central focus of the organisation of health services. It is defined as the set of activities carried out by the health care providers in order to increase the level of health and satisfaction of the population receiving services. The development of a PAI requires the analysis of the flow of activities, the inter-relationships between professionals and care teams, and patient expectations. The methodology for the development of a PAI is presented and discussed in this article, as well as the success factors for its definition and its effective implementation. It also explains, as an example, the recent PAI for Hypoglycaemia in patients with Type 2 Diabetes Mellitus developed by a multidisciplinary team and supported by several scientific societies.

Cultural Problems Associated with the Implementation of eHealth.

A major hurdle in eHealth implementation is that it is difficult to put into practice. In this study, the primary aim was to identify the main barrier associated with implementing eHealth. This study surveyed IMIA members from May to November 2015. From the results, it is clear that medical professionals were recording most of their data by hand. This paper culture is a paradigm that is difficult to break. Cultural factors are the primary barrier in eHealth implementation.

Why Patient Centered Care Coordination Is Important in Developing Countries? Contribution of the IMIA Health Informatics for Development Working Group.

UNLABELLED: Patient Centered Care Coordination (PCCC) focuses on the patient health care needs. PCCC involves the organization, the patients and their families, that must coordinate resources in order to accomplish the goals of PCCC. In developing countries, where disparities are frequent, PCCC could improve clinical outcomes, costs and patients satisfaction. OBJECTIVE: the IMIA working group Health Informatics for Development analyzes the benefits, identifies the barriers and proposes strategies to reach PCCC. METHODS: Discussions about PCCC emerged from a brief guide that posed questions about what is PCCC, why consider PCCC important, barriers to grow in this direction and ask about resources considered relevant in the topic. RESULTS: PCCC encompasses a broad definition, includes physical, mental, socio-environmental and self care. Even benefits are proved, in developing countries the lack of a comprehensive and integrated healthcare network is one of the main barriers to reach this objective. Working hard to reach strong health policies, focus on patients, and optimizing the use of resources could improve the performance in the devolvement of PCCC programs. International collaboration could bring benefits. We believe information IT, and education in this field will play an important role in PCCC. CONCLUSION: PCCC in developing countries has the potential to improve quality of care. Education, IT, policies and cultural issues must be addressed in an international collaborative context in order to reach this goal.

Endothelin-1 levels and biomarkers of oxidative stress in glaucoma patients.

To investigate the levels of endothelin-1 (ET-1), homocysteine (Hcy), vitamins A, E, B12 and folic acid in plasma of patients with different types of glaucoma: primary open-angle glaucoma (POAG) and normotensive glaucoma (NTG). Patients were classified into 3 groups: group POAG comprised 48 patients, group NTG comprised 15 patients, and control group that comprised 75 healthy subjects. ET-1 levels were measured by ELISA, Vitamins A and E by HPLC, and Vitamin B12, homocysteine, and folic acid levels were determined by chemiluminescent immunoassay. The ET-1 and Hcy levels were significantly higher (p = 0.002) in the POAG group compared to NTG and control group. Vitamin E levels were significantly lower (p = 0.001) in the NTG group compared to POAG and control group. The increase of Hcy and ET-1 in POAG patients is related to vascular endothelial dysfunction. Thus results may play a key role in the development of this disease. Lower levels of Vitamin E in the NTG group suggest that oxidative process plays an early role in the development of this type of glaucoma.

[Effectiveness and safety of Very Low Calory Diets in obese patients]. / Evaluación de la efectividad y seguridad de Dietas de Muy Bajo Contenido Calórico en pacientes obesos.

PURPOSE: To evaluate effectiveness, safety and adherence of Very Low Calory Diet (VLCD) in patients with obesity. METHODS: Observational prospective descriptive study. Patients with BMI >30 kg/m2 who started VLCD were included. We arranged 3 pharmacotherapeutical consultations, picking up the variables: age, sex, BMI, side effects and number of VLCD cycles. We defined effectiveness as weight loss in absolute and relative terms and weight loss rate (kg/week); safety as incidence and severity of side effects by the Pharmacovigilance Spanish System (SEFV); and adherence by a SMAQ adapted questionnaire. RESULTS: 29 women and 15 men were included, with a mean of 42 years. 5 patients did not complete the follow-up. Effectiveness: weight loss average was 7kg (IQR 9,5 a 5,3) and relative of 6,7%, (p < 0.0005). The weight loss rate was 1,2kg per week (IQR 1,6 a 0,9). SAFETY: 33% of the patients described side effects. All of them were mild (37% constipation, 16% dizziness, 12% anxiety, 5% headache, 2% gases y 2% epigastrical pain). ADHERENCE: 84% of the patients were adherent by the SMAQ adapted questionnaire: 74% in the first cycle and 92% in the following ones. The relation between the number of cycles and the adherence did not get statistical differences (p = 0,1127). CONCLUSIONS: Effectiveness and adherence to the treatment could improve in obese patients by setting interdisciplinary measures in the daily clinical practice.

Evaluación de la efectividad y seguridad de Dietas de Muy Bajo Contenido Calórico en pacientes obesos / Efectiveness and safety of very low calory diets in obese patients

Objetivos: Evaluar efectividad, seguridad y adherencia de Dietas de Muy Bajo contenido Calórico (DMBC) en pacientes con obesidad. Método: Estudio descriptivo prospectivo observacional. Se incluyeron pacientes con IMC >30 kg/m2 que inician tratamiento con DMBC. Se realizaron tres consultas farmacéuticas, recogiéndose las variables: edad, sexo, IMC, efectos adversos y número de ciclos de DMBC. Se definió efectividad como la pérdida de peso en términos absolutos y relativos, y la tasa de pérdida de peso kg/semana; seguridad como incidencia y gravedad de efectos adversos según el Sistema Español de Farmaco vigilancia (SEFV); y adherencia a través de un cuestionario SMAQ adaptado. Resultados: Se incluyeron 29 mujeres y 15 hombres; media de 42 años. 5 pacientes no completaron el seguimiento. Efectividad: la mediana de pérdida de peso fue de 7 kg (RIQ 9,5a 5,3) y relativa de 6,7%, (p < 0,0005). La tasa de pérdida de peso kg/semana fue de 1,2 kg (RIQ 1,6 a 0,9). Seguridad: el 33% de los pacientes refirieron efectos adversos. Todos fueron leves (37% estreñimiento, 16% mareos, 12% ansiedad, 5% cefaleas, 2% gases y 2% dolor epigástrico). Adherencia: el 84% de los pacientes fueron adherentes segúnel cuestionario SMAQ adaptado, en 1er ciclo un 74% y un 92%en sucesivos. La relación entre el número de ciclos y la adherencia, no alcanzó diferencias significativas (p = 0,1127). Conclusiones: La efectividad y la adherencia al tratamiento son mejorables a través de la implantación de medidas interdisciplinares de seguimiento activo al paciente obeso en la práctica clínica diaria

Purpose: To evaluate effectiveness, safety and adherence of Very Low Calory Diet (VLCD) in patients with obesity. Methods: Observational prospective descriptive study. Patients with BMI>30 kg/m2 who started VLCD were included. We arranged 3 pharmaco therapeutical consultations, picking up the variables: age, sex, BMI, side effects and number of VLCD cycles. We defined effectiveness as weight loss in absolute and relative terms and weight loss rate (kg/week); safety as incidence and severity of side effects by the Farmaco vigilance Spanish System (SEFV); and adherence by a SMAQ adapted questionnaire. Results: 29 women and 15 men were included, with a mean of 42years. 5 patients did not complete the follow-up. Effectiveness: weight loss average was 7kg (IQR 9,5 a 5,3) and relative of6,7%, (p < 0.0005). The weight loss rate was 1,2kg per week (IQR 1,6 a 0,9).Safety: 33% of the patients described side effects. All of them were mild (37% constipation, 16% dizziness, 12% anxiety, 5% headache,2% gases y 2% epigastrical pain).Adherence: 84% of the patients were adherent by the SMAQ adapted questionnaire: 74% in the first cycle and 92% in the following ones. The relation between the number of cycles and the adherence did not get statistical differences (p = 0,1127). Conclusions: Effectiveness and adherence to the treatment could improve in obese patients by setting interdisciplinary measures in the daily clinical practice (AU)

Sobreexpresión proteica y amplificación génica del oncogén HER2/neu en cáncer de mama: estudio de 125 casos / No disponible

Objetivo: estudiar una serie de 125 casos de cáncer demama procedentes de diferentes hospitales de la ComunidadValenciana, analizados de forma homogénea y protocolizadaen un mismo centro, comprobando el porcentaje real de casosamplificados para HER2/neu en los distintos grupos de expresiónproteica: sin sobreexpresión (0, 1+) y con sobreexpresión(2+, 3+). Determinar asimismo, el porcentaje de casos aneuploidespara el cromosoma 17 y la relación existente entre laaneuploidía y la amplificación HER2/neu. Comparar nuestrosresultados de inmunohistoquímica con los resultados en loscentros de origen.Pacientes y métodos: los métodos para la valoración delestado de HER2/neu utilizados fueron la determinación mediantetécnica inmunohistoquímica (kit HerceptestTM automatizado)para el análisis de la expresión proteica e hibridación insitu fluorescente (HER2 FISH pharmDxTM kit) para la amplificacióngénica.Resultados: de los casos con expresión proteica 3+(45/125), un 87% eran amplificados y un 13% no amplificados.De los casos 2+ (43/125) un 28% aparecían amplificadosy un 72% no amplificados. En los casos 1+/0 (37/125)un 3% estaban amplificados (1/7) y un 97% no amplificados.Adicionalmente se detectaron 36 casos aneuploides para elcromosoma 17 (29% del total), de los cuales un 31% estabanasimismo amplificados y un 69% no amplificados. La concordanciaen la determinación del Herceptest inter-centro presentaun coeficiente de correlación r = 0,527 (p < 0,01).Conclusiones: la técnica de hibridación in situ fluorescentese revela como técnica de referencia o gold standard para ladeterminación del estado del oncogen Her2/neu permitiendodiferenciar una sobreexpresión proteica producida por una“verdadera” amplificación génica, de la producida por unaaneuploidía...(AU)

Objectives: one hundred and twenty five breast tumors fromdifferent centers of the Valencian community were assessed bya consensus HER2/neu protocol in a single center. To determinateboth amplification and overexpression HER2/neu status,we investigate the real percentage of amplificated cases in thenon-overexpression (0, 1+) and overexpression (2+, 3+)groups. Furthermore, to determine the percentage of the chromosome17 aneusomy and its relationships with HER2/neuamplification. Finally, to compare our immunohistochemistry(IHC) results from those results obtained in the origin center.Patients and methods: all cases were assessed by IHC (HerceptestTMautomatized protocol) and fluorescence in situ hybridization(FISH) (HER2 FISH pharmDxTM kit) to detect HER2/neuexpression and HER2/neu amplification, respectively.Results: HER2/neu 3+ overexpression was observed in45/125 cases, showing amplification in 87% and 13% nonamplificated.The 2+ cases (43/125) showing amplification in28% and 72% non-amplificated. Finally, the 1+/0 cases wereobserved in 37/125 cases, showing amplification in 3% andin 97% non-amplificated. In addition, 36 (29%) cases showeda c17 aneusomy, 31% of those were amplificated and 69%non-amplificated. The inter-center IHC concordance displaysa correlation coefficient of r = 0.527 (p < 0.01).Conclusions: the FISH assay is the gold standard to determinatethe Her2/neu gene status, distinguishing between aHER2/neu protein overexpression due to a gene amplificationand those produced by an aneusomy. It is important to unify acommon criterion for the IHC classification to avoid differencesinter-observer as a consequence of different evaluation approaches(AU)

Fístula biliar tras hepatorrafia por traumatismo hepático. Posibilidad de tratamiento postural / Biliary fistula associated with hepatorrhaphy for liver injury. A possible postural management

No disponible

Neumatosis intestinal masiva asociada a nutrición enteral por catéter de yeyunostomía / Masive pneumatosis intestinalis associated with enteral nutrition and needle catheter

No disponible